Literature DB >> 11173542

Genetic mapping and allelic loss analysis in mouse thymic lymphomas of Helios and Aiolos belonging to the Ikaros gene family.

H Xu1, Y Wakabayashi, H Okano, Y Saito, T Miyazawa, R Kominami.   

Abstract

The Ikaros gene undergoes bi-allelic changes at a high frequency in gamma-ray-induced mouse thymic lymphomas, suggesting the relevance of Ikaros to the lymphoma development. Here we test whether Helios and Aiolos, two other members of the Ikaros gene family, are also involved in lymphomagenesis. Genetic mapping showed that Helios is located between D1Mit531 and D1Mit19 on chromosome 1 and Aiolos is between D11Mit222 and D11Mit332 on chromosome 11. Analysis using polymorphic markers around the two regions revealed that neither locus exhibited allelic loss in the 78 lymphomas that were induced in p53 wild-type mice, whereas in 102 p53(KO / + ) mouse-derived lymphomas Helios and Aiolos loci showed allelic loss in 8% (8 / 102) and 33% (34 / 102), respectively. However, 33 of the 34 lymphomas showing allelic loss at Aiolos were p53(KO / - ) and were accompanied by loss of the p53 wild-type allele on the same chromosome. Homozygous deletion and mutation analyses failed to detect bi-allelic alterations. These results do not suggest any obvious contribution of Helios or Aiolos to oncogenesis of the mouse thymic lymphomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11173542      PMCID: PMC5926589          DOI: 10.1111/j.1349-7006.2001.tb01045.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  22 in total

1.  Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment.

Authors:  K Georgopoulos; D D Moore; B Derfler
Journal:  Science       Date:  1992-10-30       Impact factor: 47.728

2.  Homozygous deletions and point mutations of the Ikaros gene in gamma-ray-induced mouse thymic lymphomas.

Authors:  H Okano; Y Saito; T Miyazawa; T Shinbo; D Chou; S Kosugi; Y Takahashi; S Odani; O Niwa; R Kominami
Journal:  Oncogene       Date:  1999-11-18       Impact factor: 9.867

3.  Enhanced proliferative potential in culture of cells from p53-deficient mice.

Authors:  T Tsukada; Y Tomooka; S Takai; Y Ueda; S Nishikawa; T Yagi; T Tokunaga; N Takeda; Y Suda; S Abe
Journal:  Oncogene       Date:  1993-12       Impact factor: 9.867

Review 4.  The complexity of p53 modulation: emerging patterns from divergent signals.

Authors:  A J Giaccia; M B Kastan
Journal:  Genes Dev       Date:  1998-10-01       Impact factor: 11.361

5.  Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin.

Authors:  K Hahm; B S Cobb; A S McCarty; K E Brown; C A Klug; R Lee; K Akashi; I L Weissman; A G Fisher; S T Smale
Journal:  Genes Dev       Date:  1998-03-15       Impact factor: 11.361

6.  Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin.

Authors:  K E Brown; S S Guest; S T Smale; K Hahm; M Merkenschlager; A G Fisher
Journal:  Cell       Date:  1997-12-12       Impact factor: 41.582

7.  A comprehensive genetic map of the mouse genome.

Authors:  W F Dietrich; J Miller; R Steen; M A Merchant; D Damron-Boles; Z Husain; R Dredge; M J Daly; K A Ingalls; T J O'Connor
Journal:  Nature       Date:  1996-03-14       Impact factor: 49.962

8.  The lymphoid transcription factor LyF-1 is encoded by specific, alternatively spliced mRNAs derived from the Ikaros gene.

Authors:  K Hahm; P Ernst; K Lo; G S Kim; C Turck; S T Smale
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

9.  Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.

Authors:  M Harvey; M J McArthur; C A Montgomery; J S Butel; A Bradley; L A Donehower
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

10.  A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma.

Authors:  S Winandy; P Wu; K Georgopoulos
Journal:  Cell       Date:  1995-10-20       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.